Le Lézard
Classified in: Health, Business
Subjects: MAV, ERN, CCA, MAT

Canopy Growth to Announce Second Quarter Fiscal 2019 Financial Results


SMITHS FALLS, ON, Oct. 15, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) will release its financial results for the second quarter fiscal 2019 ended September 30, 2018 on November 14, 2018.

Following the release of its second quarter 2019 financial results, Canopy Growth will host a conference call and audio webcast with Bruce Linton, Chairman & Co-CEO and Tim Saunders, EVP & CFO at 8:30 AM Eastern Time the same day.

Webcast Information
A live audio webcast will be available at: https://event.on24.com/wcc/r/1861049/FFEFED61C13E0E47609599A4EBD15422

Calling Information
Toll Free Dial-In Number: 1-888-231-8191 
International Dial-In Number: (647) 427-7450 
Conference ID: 4578825

Replay Information
A replay of the call will be accessible by telephone until 11:59 PM ET on February 12, 2019. 
Toll Free Dial-in Number: 1-855-859-2056
Replay Password: 4578825

Here's to Future Growth.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in 12 countries across five continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet of GMP certified production space. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements 
This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to US market participation and/or the establishment of US-based operations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the opening of stores; planning of unveiling events; product availability; and such risks contained in the Company's Management Information Circular dated August 22, 2018 and annual information form dated June 28, 2018 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

 

SOURCE Canopy Growth Corporation


These press releases may also interest you

at 11:15
Variantyx, a leader in molecular diagnostics, announced today that it has secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures....

at 11:03
The heart of Vajra Coffee's natural decaffeination process lies in its adoption of the Swiss Water® Process, a natural method that removes 99% of caffeine...

at 11:00
United Imaging Healthcare (SSE:688271) has published its 2023 Environment, Social, and Governance (ESG) Report, reaffirming its mission to bring Equal Healthcare for All. This report highlights the company's advancements in corporate responsibility,...

at 11:00
United Imaging Healthcare (SSE:688271), a global leader in manufacturing advanced medical imaging and radiotherapy equipment, has released their 2023 annual report. The report reveals that the company achieved 11.41 billion CNY in revenue in 2023,...

at 10:54
Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSAtm (vibegron under the international...

at 10:49
Sustain Exchange LLC is proud to announce a partnership with HearMe, a leading behavioral health peer support platform focused on ensuring healthy lives and promoting well-being. As part of this innovative partnership, SustainAble Exchange will...



News published on and distributed by: